IPC
BMRN icon

Independent Portfolio Consultants’s BioMarin Pharmaceuticals BMRN Stock Holding History

Independent Portfolio Consultants’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$78K Sell
854
-296
-26% -$26.9K 0.03% 446
2017
Q1 		$101K Sell
1,150
-115
-9% -$10.2K 0.03% 450
2016
Q4 		$105K Sell
1,265
-45
-3% -$3.87K 0.03% 433
2016
Q3 		$121K Buy
+1,310
New +$123K 0.04% 422

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Independent Portfolio Consultants's BMRN Position: Q2 2017 in Review

Independent Portfolio Consultants reduced its BioMarin Pharmaceuticals (BMRN) stake by 26% in Q2 2017, selling an estimated $26.9K and leaving 854 shares worth $78K. The position accounts for 0.03% of the portfolio, ranked #446.

Independent Portfolio Consultants first reported a position in BMRN in Q3 2016 and has held it in 4 quarters since. The position peaked at $121K in Q3 2016. 426 funds tracked by Wall St. Rank hold BMRN as of Q2 2017.

  • Independent Portfolio Consultants held 854 shares of BioMarin Pharmaceuticals worth $78K as of Q2 2017.
  • Independent Portfolio Consultants sold 296 BioMarin Pharmaceuticals shares in Q2 2017, an estimated $26.9K.
  • BioMarin Pharmaceuticals made up 0.03% of Independent Portfolio Consultants's portfolio in Q2 2017, its #446 holding.
  • Independent Portfolio Consultants first reported a position in BioMarin Pharmaceuticals in Q3 2016 and has held it in 4 quarters since.
  • Independent Portfolio Consultants's BioMarin Pharmaceuticals position peaked at $121K in Q3 2016.
  • 426 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2017.

Based on Independent Portfolio Consultants's 13F filing for Q2 2017, filed 6 Jul 2017.